What is this?
USP <901> asbestos in talc testing is a regulated testing workflow that should address asbestos reference standards, positive and negative controls, XRPD and PLM method execution, sample preparation, and method verification.
Start with the regulated decision
Use our cGMP XRPD and PLM validated USP procedures, qualified reference standards, representative sampling, and defensible documentation for talc testing.
For cGMP work, method choice has to follow the quality attribute, sample matrix, method status, documentation need, and regulatory decision. The testing plan should connect method development, validation, method transfer, release testing, CoA support, and documentation requirements rather than treating each instrument run as an isolated activity.
Overview of USP 901 Asbestos in Talc Testing Services
When is it used?
Use it when talc raw materials or products require asbestos evaluation for quality, supplier qualification, complaint investigation, release, or regulatory scrutiny.
What are limitations?
False negatives can occur when sampling is not representative, sample preparation destroys or masks fibers, reference standards are weak, analysts are not trained, or only one technique is used without verification.
What sample amounts are needed?
Amounts depend on lot heterogeneity, number of subsamples, method verification, spike recovery, retains, and whether XRPD and PLM are both run.
What techniques compete with it?
USP <901> emphasizes XRPD and PLM testing only. SEM/EDX, microscopy, Raman/FTIR, or additional mineralogical testing may be orthogonal depending on the investigation.
What does FDA care about?
FDA cares that the method is scientifically justified, specific for the intended attribute in the real matrix, controlled under the quality system, validated or verified where appropriate, data-integrity compliant, and lifecycle managed.
What are common mistakes?
Common mistakes include using exploratory data as release evidence, validating the wrong matrix, ignoring sample preparation, under-documenting controls, relying on one technique when orthogonal evidence is needed, or failing to define the decision before testing.
What is Triclinic's experience with this technique
Triclinic applies USP <901> asbestos-in-talc testing to real-world raw-material, supplier-qualification, release, investigation, and compliance questions where regulated talc materials require controlled microscopy and mineralogical evidence. We have tested samples form all over the world for the presence of asbestos in talc. The validated cGMP procedures support quality decisions by documenting preparation, examination, observations, review, and reporting in a form suitable for regulated use and follow-up investigations.
What changes when the work is cGMP?
Exploratory data can help choose a method, but release or filing-support data require controlled execution. The method must be suitable for the matrix, the quality attribute must be defined, reference standards and controls must be appropriate, and the report or CoA must say only what the data support.
| cGMP concern | Why it matters | Practical control |
|---|---|---|
| Method status | Exploratory, verified compendial, validated custom, and transferred methods have different evidence requirements. | Define status before testing and document any development, verification, validation, or transfer work. |
| Sample matrix | Specificity can fail in real drug product, excipient, talc, low-dose, or complex solid mixtures. | Use representative material, placebo/matrix controls, spike studies, or orthogonal methods where needed. |
| Data integrity | Release or stability results must survive QA review, audit, and regulatory scrutiny. | Use controlled records, system suitability, analyst review, deviations/OOS process, and traceable calculations. |
Specific instruments and capabilities for Asbestos in Talc Testing
The table below lists the specific platforms, brands, models, software, detectors, and capability notes relevant to this cGMP service area.
| Instrument or platform | Brand, model, software, or detector | Additional capabilities and use |
|---|---|---|
| Polarized-light microscopy (USP <901> Procedure 1) | Leica DM2500P compound microscope; polarizing-light microscope; Pax-it2! v.1.4.3 software | cGMP USP Verified Optical and polarized-light particle examination, birefringence, morphology, and visual classification support for talc/asbestos investigations. |
| Powder X-ray diffraction (USP <901> Procedure 2) | Rigaku SmartLab instruments; Cu source; 1D and 2D, reflection and transmission orientations | cGMP USP Verified Phase identification, crystalline-material fingerprinting, and orthogonal solid-form/mineral identification support. |
| SEM/EDX | Thermo Phenom XL with fully integrated EDX and BSE detector | High-vacuum/low-vacuum SEM imaging, BSE contrast, and integrated elemental analysis for suspect particles. |
| EDX detector system | Oxford INCA PentFETx3 EDX | Elemental spectra, spot/region analysis, and elemental maps for foreign-particle and contaminant investigations. |
| FT-IR | Thermo iS50 Model 60825 and Nicolet 6700; ATR, diffuse reflectance, transmission, gas cell; DTGS detector; OMNIC v.9.7.46 software | Functional-group identification and spectral-library matching to support mineral or excipient identity questions. |
USP <901> Talc Testing Readiness: XRPD, PLM, Controls, and Documentation
This example frames USP <901> talc testing as a readiness problem: the method must address representative sampling, XRPD and PLM execution, reference standards, positive and negative controls, sample preparation, and cGMP documentation before the result can support release, supplier qualification, or regulatory scrutiny. XRPD helps identify accessory minerals and amphibole/serpentine minerals, while PLM provides lower-level particle evidence and optical differentiation, so the testing program has to control both method execution and interpretation.
| USP <901> readiness element | Regulated implication |
|---|---|
| XRPD screening (Procedure 2) | Supports phase/mineral identification and assessment of accessory minerals in talc. |
| PLM examination (Procedure 1) | Adds particle-level optical evidence for suspected asbestos and morphology-based differentiation. |
| Reference standards and controls | Needed to demonstrate that the method can detect relevant asbestos/mineral targets and avoid false confidence. |
| Representative sampling and documentation | Critical because talc contamination can be heterogeneous and regulatory conclusions depend on the sampled material. |
Technical Resources and Publications
These examples cite Triclinic source documents, regulatory guidance, or literature relevant to this our Talc testing services. Download buttons are positioned at the bottom-left of each example.
Questions You Should Be Asking a USP <901> cGMP Asbestos in Talc Testing Lab
Author: Triclinic Labs
Publication date: 2026
Abstract: This Triclinic reference frames USP <901> talc testing around reference standards, controls, XRPD and PLM execution, representative sample preparation, method verification, LOD/LOQ, spike recovery, and defensible documentation.
USP <901> Official-Date Communication for Asbestos Testing in Talc
Author: United States Pharmacopeia (USP)
Publication date: 2025
Abstract: USP communicated that the official timing for Talc monograph <901> asbestos requirements has been deferred to June 1, 2026. The update is directly relevant to pharmaceutical talc suppliers and drug-product manufacturers preparing XRPD and PLM methods, reference standards, sample controls, verification/validation records, and audit-ready documentation before the official date.
ICH Q2(R2) Validation of Analytical Procedures and ICH Q14 Analytical Procedure Development
Author: International Council for Harmonisation / FDA
Publication date: 2024
Abstract: These harmonized guidances describe validation and development principles for analytical procedures used to assess drug-substance and drug-product quality. They anchor expectations for specificity, accuracy, precision, range, robustness, lifecycle management, and fit-for-purpose method evidence in cGMP work.
Related cGMP services
NMR
Use cGMP NMR for identity, purity, qNMR, reference-material verification, method development, validation, and release testing.
View serviceXRPD
Use cGMP XRPD for solid-form identification, polymorph or phase quantitation, crystallinity, method validation, release, and stability support.
View serviceParticle Size Analysis
Develop, validate, verify, and transfer wet or dry particle-size methods for release specifications and quality decisions.
View serviceThermal Analysis (TGA/DSC)
Use cGMP DSC and TGA to evaluate melting, desolvation, dehydration, glass transitions, degradation, and thermal material control.
View serviceRaman / FTIR
Use cGMP Raman and FTIR for raw-material ID, solid-form differentiation, mapping, contaminant ID, and validated spectroscopic methods.
View serviceMorphology
Use cGMP microscopy and particle morphology evidence for identification, particle shape, foreign-material work, and regulated investigations.
View serviceCommon questions
When should USP 901 Asbestos in Talc Testing be run under cGMP?
Run the work under cGMP when the result will support release, stability, regulatory documentation, method validation or transfer, CoA issuance, or a quality investigation rather than exploratory screening only.
How much material should be submitted?
Material requirements depend on method, matrix, replicate design, standards, destructive testing, retain needs, and whether method development, validation, transfer, or release testing is required. Confirm exact amounts before shipment. Typically multigram scale amounts are provided
Are Procedure 1 and 2 Verified in your lab?
Yes. Both USP procedures have been verified/validated as have the refernece materials.
What makes the result defensible?
Defensible cGMP results require appropriate method status, sample traceability, reference standards, controls, system suitability, analyst training, data review, and clear reporting of limitations.
Do you develop, validate, and transfer methods?
Yes. Triclinic can develop, validate, verify, and transfer methods where the compendial or client-required approach needs controlled implementation. For USP <901> work this can include XRPD and PLM method controls, reference materials, sample preparation, system suitability, analyst training, specificity, detection capability, reporting limits, and documentation that supports cGMP review.
Why are both XRPD and PLM relevant to USP 901 talc testing?
XRPD and PLM provide different evidence. XRPD evaluates crystalline phases in the bulk sample, while PLM examines particle morphology and optical properties. Representative sampling, qualified standards, and method-specific controls are critical to both.
Discuss cGMP Talc testing requirements
Contact us for information on USP <901> testing for asbestos in talc using cGMP verified Procedures 1 and 2.